<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01910259</url>
  </required_header>
  <id_info>
    <org_study_id>12/0219</org_study_id>
    <nct_id>NCT01910259</nct_id>
  </id_info>
  <brief_title>MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial</brief_title>
  <acronym>MS-SMART</acronym>
  <official_title>A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MS Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Keele University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Warwick</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College, London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multiple sclerosis (MS) is a disabling and progressive neurological disease that affects&#xD;
      approximately 100,000 people in the UK. Many patients with MS experience two phases of&#xD;
      disease; early MS (also called relapsing remitting MS, RRMS) and late MS (also called&#xD;
      secondary progressive MS (SPMS). Early MS is due to inflammation of the nerves and the&#xD;
      insulation (called myelin) that surrounds the nerves. Early MS is often characterised by&#xD;
      periods of &quot;attacks&quot; interspersed with periods of &quot;remission&quot; with no or low disease&#xD;
      symptoms. Late or progressive MS, which affects the majority of patients and typically&#xD;
      emerges after 10-15 years of disease, results from actual nerve death (also called&#xD;
      neurodegeneration). The progressive stage of disease results not in individual attacks but&#xD;
      slow, cumulative and irreversible disability affecting walking, balance, vision, cognition,&#xD;
      pain control, bladder and bowel function. Critically, and unlike early disease, there is no&#xD;
      proven treatment for the late stage of MS. This is therefore an urgent and major unmet health&#xD;
      need. MS-SMART directly addresses this need and will evaluate in this clinical trial three&#xD;
      drugs (fluoxetine, riluzole or amiloride), all of which have shown some promise in MS, and in&#xD;
      particular in SPMS. The trial is randomised and blinded. Randomisation means patients can get&#xD;
      any one of the three active drugs or the inactive placebo/dummy; blinded means that neither&#xD;
      patients nor the doctors will know which drug or placebo patients are receiving.&#xD;
      Randomisation and blinding are standard approaches in clinical trials to ensure unbiased&#xD;
      testing of drugs. All patients in MS-SMART will have periodic MRI (magnetic resonance&#xD;
      imaging) brain scans and after 96 weeks these will be analysed. We will then compare the&#xD;
      scans of each drug to the placebo or dummy to see if any of the drugs slow the rate of brain&#xD;
      shrinkage that normally occurs in SPMS. This measured change in brain size is the primary&#xD;
      (major) outcome of MS-SMART.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MS-SMART will test the efficacy and mechanism of action of three repurposed drugs&#xD;
      (fluoxetine, riluzole and amiloride). All three drugs are in human use and have a good safety&#xD;
      record. Critically for the purpose of MS-SMART they all have shown promise in early phase&#xD;
      human MS clinical trials and target one or more of the pivotal neurodegenerative causing&#xD;
      pathways implicated in SPMS. This is a Type B trial, as the IMPs are all in human use, have a&#xD;
      good safety profile but are not currently used for this patient population.&#xD;
&#xD;
      The major need for patients with established and progressive MS is neuroprotective or disease&#xD;
      modifying treatments that will slow or even stop disease progression. This study will&#xD;
      evaluate three highly promising putative neuroprotective drugs as well as comprehensively&#xD;
      address several of the current knowledge gaps related to the understanding of neuroprotection&#xD;
      and neurodegeneration in SPMS through MRI and CSF examination.&#xD;
&#xD;
      MS-SMART is a multicentre, multi-arm, double blind, placebo-controlled phase IIb randomised&#xD;
      controlled trial. A total of 440 patients with SPMS, with an entry criteria of an EDSS score&#xD;
      of 4.0-6.5 will be equally randomised to receive placebo or one of the three active agents&#xD;
      (fluoxetine 20mg bd, amiloride 5mg bd or riluzole 50mg bd). Patients will be followed up for&#xD;
      96 weeks with outcome-data collected after 0, 24, 48 and 96 weeks. That is, the duration of&#xD;
      the trial for a trial participant is 96 weeks (a telephone assessment at week 100, 4 weeks&#xD;
      post completion will be conducted). This is standard practice for phase II trials in SPMS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 18, 2014</start_date>
  <completion_date type="Actual">July 4, 2018</completion_date>
  <primary_completion_date type="Actual">June 14, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI-derived Percentage Brain Volume Change (PBVC).</measure>
    <time_frame>2 years</time_frame>
    <description>To establish whether a drug, from a panel of 3 leading candidate neuroprotective drugs, slows the rate of brain volume loss in SPMS over 96 weeks using MRI-derived percentage brain volume change (PBVC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multi-arm trial strategy assessment</measure>
    <time_frame>2 years</time_frame>
    <description>To establish that a multi-arm trial strategy is an efficient way of screening drugs in SPMS and can become the template for future work.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of new and enlarging T2 lesions</measure>
    <time_frame>2 years</time_frame>
    <description>To explore any anti-inflammatory drug activity using the count of new and enlarging T2 lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pseudo-atrophy</measure>
    <time_frame>6 months</time_frame>
    <description>Examining for evidence of pseudo-atrophy (to ensure reliability of the primary outcome measure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical measure of neuroprotection</measure>
    <time_frame>2 years</time_frame>
    <description>To examine the clinical effect of neuroprotection as measured by clinician - EDSS, MSFC, SDMT, SLCVA, relapse rate and patient reported outcome measures - MSIS29 v2, MSWS v2, Pain - NPRS and BPI and Fatigue - NFI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics</measure>
    <time_frame>2 years</time_frame>
    <description>To collect basic health economic data (EQ-5D) to inform future phase III trials.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>New T1 hypotense lesion count</measure>
    <time_frame>2 years</time_frame>
    <description>Persistent new T1 hypointense lesion count to assess neuroprotection in new lesions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Grey matter volume change</measure>
    <time_frame>2 years</time_frame>
    <description>Grey matter volume change to assess cortical neuroprotection.</description>
  </other_outcome>
  <other_outcome>
    <measure>MR spectroscopy measured N-acetyl aspartate, myoinositol and glutamate</measure>
    <time_frame>2 years</time_frame>
    <description>MR spectroscopy (MRS) to measure N-acetyl aspartate (reversal of neuronal mitochondrial dysfunction), myoinositol (prevention of glial cell inflammation) and glutamate (prevention of excitotoxicity).</description>
  </other_outcome>
  <other_outcome>
    <measure>Myelination</measure>
    <time_frame>2 years</time_frame>
    <description>Magnetic Transfer Ratio (MTR) to evaluate myelination.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cervical cord imaging</measure>
    <time_frame>2 years</time_frame>
    <description>Cervical cord imaging to assess cord neuroprotection.</description>
  </other_outcome>
  <other_outcome>
    <measure>Composite MRI/disability scores</measure>
    <time_frame>2 years</time_frame>
    <description>Composite MRI/disability scores to increase sensitivity and study interaction of treatment mechanisms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cerebrospinal fluid (CSF) neurofilament levels</measure>
    <time_frame>2 years</time_frame>
    <description>Quantification of Cerebrospinal fluid (CSF) neurofilament levels to measure neuroprotection.</description>
  </other_outcome>
  <other_outcome>
    <measure>Optical Coherence Tomography (OCT) measured Retinal Nerve Fibre Layer (RNFL) thickness</measure>
    <time_frame>2 years</time_frame>
    <description>Optical Coherence Tomography (OCT) measured Retinal Nerve Fibre Layer (RNFL) thickness as a measure of neuroprotection.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">445</enrollment>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Amiloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amiloride 5 mg twice per day (5 mg once per day for first 4 weeks) for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Riluzole 50 mg twice per day (50 mg once per day for first 4 weeks) for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluoxetine 20 mg twice per day (20 mg once per day for first 4 weeks) for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo 1 capsule twice per day (1 capsule a day for first 4 weeks) for 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiloride</intervention_name>
    <description>Comparison with placebo</description>
    <arm_group_label>Amiloride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riluzole</intervention_name>
    <description>Comparison with placebo</description>
    <arm_group_label>Riluzole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <description>Comparison with placebo</description>
    <arm_group_label>Fluoxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of SPMS. Steady progression rather than relapse must be the major&#xD;
             cause of increasing disability in the preceding 2 years. Evidence of progression,&#xD;
             either an increase of at least one point in EDSS or clinical documentation of&#xD;
             increasing disability in patient notes&#xD;
&#xD;
          -  Expanded Disability Status Scale (EDSS) 4.0-6.5&#xD;
&#xD;
          -  Aged 25 to 65 inclusive&#xD;
&#xD;
          -  Women and men with partners of childbearing potential must be using an appropriate&#xD;
             method of contraception to avoid any unlikely teratogenic effects of the 3 drugs from&#xD;
             time of consent, to 6 weeks after treatment inclusive&#xD;
&#xD;
          -  Women must have a negative pregnancy test within 7 days prior to the baseline visit&#xD;
             unless not of child bearing potential (e.g. have undergone a hysterectomy, bilateral&#xD;
             tubal ligation or bilateral oophorectomy or they are postmenopausal)&#xD;
&#xD;
          -  Willing and able to comply with the trial protocol (e.g. can tolerate MRI and fulfils&#xD;
             the requirements for MRI, e.g. not fitted with pacemakers or permanent hearing aids),&#xD;
             ability to understand and complete questionnaires&#xD;
&#xD;
          -  Written informed consent provided&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeding patients&#xD;
&#xD;
          -  Baseline MRI scan not of adequate quality for analysis (e.g. too much movement&#xD;
             artefact)&#xD;
&#xD;
          -  Significant organ co-morbidity (e.g. malignancy or renal or hepatic failure)&#xD;
&#xD;
          -  Relapse within 3 months of baseline visit&#xD;
&#xD;
          -  Patients who have been treated with iv or oral steroids for an MS relapse/progression&#xD;
             within 3 months of baseline visit (these patients can undergo future screening visits&#xD;
             once the 3 month window has expired), patients on steroids for another medical&#xD;
             condition may enter as long as the steroid prescription is not for multiple sclerosis&#xD;
             (relapse/ progression).&#xD;
&#xD;
          -  Use of Simvastatin at 80mg dose within 3 months of baseline visit (lower doses of&#xD;
             Simvastatin and other statins are permissible)&#xD;
&#xD;
          -  Commencement of fampridine within 6 months of baseline visit&#xD;
&#xD;
          -  Use of immunosuppressants (e.g. azathioprine, methotrexate, cyclosporine) or disease&#xD;
             modifying treatments (β-interferons, glatiramer) within 6 months of baseline visit&#xD;
&#xD;
          -  Use of fingolimod/fumarate/teriflunomide/laquinomod/or other experimental disease&#xD;
             modifying treatment (including research of an investigational medicinal product)&#xD;
             within 12 months of baseline visit&#xD;
&#xD;
          -  Use of mitoxantrone/ natalizumab/ alemtuzumab/ daclizumab if treated within 12 months&#xD;
             of baseline visit&#xD;
&#xD;
          -  Primary progressive MS&#xD;
&#xD;
          -  Relapsing-remitting MS&#xD;
&#xD;
          -  Known hypersensitivity to the active substances and their excipients to any of the&#xD;
             active drugs for this trial&#xD;
&#xD;
          -  Use of: lithium, chlorpropamide, triamterene and spironolactone within 6 months of the&#xD;
             baseline visit&#xD;
&#xD;
          -  Current use of potassium supplements&#xD;
&#xD;
          -  Current use of tamoxifen&#xD;
&#xD;
          -  Current use of herbal treatments containing St. John's Wort&#xD;
&#xD;
          -  Significant signs of depression&#xD;
&#xD;
          -  Use of an SSRI within 6 months of the baseline visit&#xD;
&#xD;
          -  Use of monoamine oxidase inhibitors, phenytoin, L-tryptophan) and/or neuroleptic drugs&#xD;
             within 6 months of the baseline visit&#xD;
&#xD;
          -  A Beck Depression Index score of 19 or higher&#xD;
&#xD;
          -  Bipolar disorder&#xD;
&#xD;
          -  Receiving or previously received Electro-Convulsive Therapy&#xD;
&#xD;
          -  Epilepsy/seizures&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Patients with a history of bleeding disorders or currently on anticoagulants Routine&#xD;
             screening blood values (LFT) &gt;/ 3 x upper limit of normal (ULN) of site reference&#xD;
             ranges (ALT/AST, bilirubin,ˠGT) Potassium &lt;2.8mmol/l or &gt;5.5mmol/l&#xD;
&#xD;
          -  Sodium &lt;125mmol/l&#xD;
&#xD;
          -  Creatinine &gt;130μmol/l&#xD;
&#xD;
          -  WBCs &lt;3 x 109/l&#xD;
&#xD;
          -  Lymphocytes &lt;0.8 x 109/l&#xD;
&#xD;
          -  Neutrophil count &lt;1.0 x 109 /l&#xD;
&#xD;
          -  Platelet count &lt;90 x 109 /l&#xD;
&#xD;
          -  Haemoglobin &lt;80g/l&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Chataway</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Siddharthan Chandran</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anne Rowling Regenerative Neurology Clinic, Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gartnavel Royal Hospital, 1055 Great Western Road</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 OXH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brighton and Sussex University Hospitals</name>
      <address>
        <city>Haywards Heath</city>
        <zip>RH16 4EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Walton Centre</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The National hospital for Neurology and Neurosurgery, University College London</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital, Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Staffordshire</name>
      <address>
        <city>Stoke-on-Trent</city>
        <zip>ST4 7LN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://ms-smart.org</url>
    <description>Trial website</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 19, 2013</study_first_submitted>
  <study_first_submitted_qc>July 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <last_update_submitted>March 25, 2020</last_update_submitted>
  <last_update_submitted_qc>March 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary Progressive Multiple Sclerosis</keyword>
  <keyword>Neuroprotective</keyword>
  <keyword>Repurposed drugs</keyword>
  <keyword>Brain atrophy</keyword>
  <keyword>Percentage Brain Volume Change</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Optical Coherence Tomography</keyword>
  <keyword>Cerebrospinal fluid</keyword>
  <keyword>Amiloride</keyword>
  <keyword>Riluzole</keyword>
  <keyword>Double blind</keyword>
  <keyword>Placebo</keyword>
  <keyword>Fluoxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiloride</mesh_term>
    <mesh_term>Riluzole</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

